SCHEMBL23325914

SCHEMBL23325914

CCN(C)C(=O)c1ccc(NC(C)C)cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P4HTM Q9NXG6 5/20 0.36
▸ NAMPT P43490 1/20 0.36
▸ HDAC3 O15379 3/20 0.36
▸ HDAC1 Q13547 3/20 0.36
▸ HDAC8 Q9BY41 3/20 0.36
▸ HDAC4 P56524 2/20 0.36
▸ HDAC6 Q9UBN7 2/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.35
▸ HCAR3 P49019 1/20 0.34
▸ ABL1 P00519 1/20 0.34
▸ PIM1 P11309 1/20 0.34
▸ CSNK2A1 P68400 1/20 0.34
▸ MAPT P10636 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ GFER P55789 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23323560 0.82 P4HTM (0.38) P4HTMHDAC3HDAC1HDAC8HDAC4
SCHEMBL3261360 0.75 TRPM8 (0.38) MAPTKDM4EALDH1A1TDP1MEN1
SCHEMBL16545869 0.75 TDP1 (0.50) P4HTMHDAC6MAPTKDM4EALDH1A1
SCHEMBL30503685 0.73 KDM4E (0.43) P4HTMNAMPTMAPTKDM4EALDH1A1
SCHEMBL29024939 0.73 KDM4E (0.43) P4HTMNAMPTMAPTKDM4EALDH1A1
SCHEMBL25932371 0.71 P4HTM (0.36) P4HTMHDAC3HDAC1HDAC8HDAC4
SCHEMBL25905786 0.71 HCAR3 (0.61) NAMPTHCAR3KDM4EALDH1A1POLB
SCHEMBL25905785 0.71 ADRA2A (0.40) P4HTMHDAC3HDAC1HDAC8HDAC4
SCHEMBL25041234 0.70 ADRA2A (0.44) P4HTMHDAC3HDAC1HDAC8HDAC4
SCHEMBL22341854 0.68 P4HTM (0.44) P4HTMHDAC3HDAC1HDAC8HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234929-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 — — US disclosed
US-11566007-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2023-01-31 — — US disclosed
US-20210130303-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2021-05-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11566007-B2 Ras inhibitors KRAS, NRAS, HRAS P4HTM 3119/4885NAMPT 2731/4885HDAC3 2510/4885
US-20230234929-A1 RAS INHIBITORS KRAS, NRAS, HRAS P4HTM 3119/4885NAMPT 2731/4885HDAC3 2510/4885
US-20210130303-A1 RAS INHIBITORS KRAS, NRAS, HRAS P4HTM 3119/4885NAMPT 2731/4885HDAC3 2510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback